Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
KVHI$7.78+0.05(+0.65%)KVH Industries to Host Third Quarter Conference Call on November 5, 2026[9:22:13 AM ET]ARAI$0.11-0.01(-5.93%)Arrive AI to Report Q3 2026 Results and Host Webcast on November 13[9:19:00 AM ET]VIVK$1.73+0.23(+15.33%)Vivakor Announces Proposed Hydrogen Plant and Fueling Station at a Texas International Airport[9:15:00 AM ET]KBLB$0.080.00(0.00%)Why Kraig Labs’ Spider Silk Could Have a Future in Aerospace[9:15:00 AM ET]CWBK$41.000.00(0.00%)CW Bancorp Reports Third Quarter 2026 Financial Results CW Bancorp (OTCQX: CWBK), the parent company ("the Company") of CommerceWest Bank (the "Bank") reported consolidated net income for the third quarter ...[9:15:00 AM ET]NTHI$3.16+0.04(+1.25%)NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage[9:10:00 AM ET]CURLF$8.59+0.11(+1.27%)Curaleaf Celebrates Graduation of Inaugural New York Incubator Program Class, Announces Future Cohorts and Multi-State Expansion Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf"), a leading international provider of consumer cannabis products, today announced the...[9:10:00 AM ET]PTHS$21.39+4.85(+29.32%)Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin[9:09:49 AM ET]IDAI$2.95+0.09(+3.15%)Trust Stamp Appointed Exclusive Technology Partner for AFCAS, Ghana’s National Fire Safety Digitisation Programme[9:07:00 AM ET]XE$11.09-0.61(-5.26%)NRC Completes Landmark Safety Review of X-energy’s Xe-100 SMR[9:06:55 AM ET]AKTX$8.00-1.20(-13.04%)Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit[9:05:00 AM ET]SNDX$14.04-0.11(-0.78%)Syndax’s Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases[9:01:00 AM ET]GIGM$1.30+0.06(+5.28%)GigaMedia Announces Third-Quarter 2026 Financial Results GigaMedia Limited (NASDAQ: GIGM) today announced its third-quarter 2026 unaudited financial results. Comments from Management In the third quarter of ...[9:00:00 AM ET]

INTS · NASDAQ

Intensity Therapeutics, Inc.

$3.66 +0.32 (+9.58%)

Company overview

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors, as well as pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has collaboration agreements with Merck Sharpe & Dohme Corp.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$9.9M
Employees
5
Headquarters
Westport, CT
Website
intensitytherapeutics.com
CEO
Lewis H. Bender
Listed
June 30, 2023
P/E
-0.53
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$7,000
Operating income
-$11.1M
EBITDA
-$8.3M
Net income
-$10.7M
EPS
-$6.97
Total assets
$12.3M
Total debt
$102,000
Earnings yield
-190.44%

Price chart

2.913.544.184.815.44
INTS 1D NASDAQ O3.29H3.41L3.29C3.34-0.04 (-1.18%)Vol4.35K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
INTSIntensity Therapeutics, Inc. Press release Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026 Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery an… PR Newswire
INTSIntensity Therapeutics, Inc. Press release Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical On… PR Newswire
INTSIntensity Therapeutics, Inc. Press release Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference PRNewsWire
INTSIntensity Therapeutics, Inc. Stock news Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript Seeking Alpha
INTSIntensity Therapeutics, Inc. Press release Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update PRNewsWire
INTSIntensity Therapeutics, Inc. Press release Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 PRNewsWire
INTSIntensity Therapeutics, Inc. Press release Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) PRNewsWire
INTSIntensity Therapeutics, Inc. Press release Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 PRNewsWire
INTSIntensity Therapeutics, Inc. Stock news Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why Zacks Investment Research
INTSIntensity Therapeutics, Inc. Press release Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award PRNewsWire
INTSIntensity Therapeutics, Inc. Press release Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update PRNewsWire
INTSIntensity Therapeutics, Inc. Stock news Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now Zacks Investment Research
INTSIntensity Therapeutics, Inc. Stock news Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know Zacks Investment Research
INTSIntensity Therapeutics, Inc. Press release Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation PRNewsWire
INTSIntensity Therapeutics, Inc. Press release Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update PRNewsWire
INTSIntensity Therapeutics, Inc. Press release Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US PRNewsWire
INTSIntensity Therapeutics, Inc. Stock news Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause Benzinga
INTSIntensity Therapeutics, Inc. Press release Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study PRNewsWire
INTSIntensity Therapeutics, Inc. Press release Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement PRNewsWire
INTSIntensity Therapeutics, Inc. Press release Intensity Therapeutics Announces Reverse Stock Split PRNewsWire
See more
FAQ

Questions about Intensity Therapeutics, Inc.

What does Intensity Therapeutics, Inc. do?
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors, as well as pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has collaboration agreements with Merck Sharpe & Dohme Corp.
What is INTS's market cap?
Intensity Therapeutics, Inc. (INTS) is a listed stock with a live quote. The latest market cap on this page is $9.9M.
Where is Intensity Therapeutics, Inc. headquartered?
Intensity Therapeutics, Inc. is headquartered in Westport, CT.
How do I get INTS news from the API?
Call GET /v1/news?tickers=INTS. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does INTS news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for INTS, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the INTS price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs